How could the presentation of new biomarker data affect the European Medicines Agency?
Positive biomarker data from ACUITY trial strengthens Privosegtor's regulatory case with EMA. The presentation of new translational data from the Phase 2 ACUITY trial provides critical insight into the biological pathways of optic neuritis and the neuroprotective potential of Privosegtor. This data, which evaluates circulating neuroaxonal and neuroinflammatory biomarkers like plasma neurofilament light chain (NfL) and glial fibrillary acidic protein (GFAP), strengthens the overall clinical evidence package for the drug. Since Privosegtor already holds Priority Medicines (PRIME) designation from the European Medicines Agency, this detailed scientific readout supports the EMA's ongoing review and decision-making process for the drug's future development.
- Effect
- Mild positive
- How direct
- Stated in the reporting
- When
- Within weeks
- The story
- Gone quiet
How it reaches European Medicines Agency
-
Oculis Holding AG announced that new biomarker information from the Phase 2 ACUITY trial of Privosegtor will be presented at the 10th Joint ACTRIMS-ECTRIMS Meeting in Toronto, Canada, on October 21-23, 2026. The presentation will detail analyses of plasma neurofilament light chain (NfL) and glial fibrillary acidic protein (GFAP) in patients with acute optic neuritis. Céline Louapre is the principal investigator of the ACUITY Phase 2 trial.
The full event1independent outlet -
The positive results from the Phase 2 ACUITY trial showed Privosegtor’s neuroprotective potential, evidenced by improved visual function and reduced neurofilament levels in the blood. This evidence is vital as Oculis is planning an IND submission for acute MS relapses and is building on this dataset for its regulatory path with the EMA.
1 report connects these two. Brind only summarizes; follow a link to read the reporting itself.
- manilatimes.net Oct 20
-
highest regulatory authority on medicines in the European Union
Everything about European Medicines Agency
Tap any step to see the evidence behind it.
The facts so far
As reported. Each one links to where it comes from.
- The presentation featured new analyses evaluating plasma neurofilament light chain (NfL) and glial fibrillary acidic protein (GFAP) in acute optic neuritis patients.manilatimes.net
- Privosegtor was granted Priority Medicines (PRIME) designation from the EMA.manilatimes.net
- Positive results from the ACUITY Phase 2 trial showed Privosegtor’s neuroprotective potential.manilatimes.net
- Oculis plans to file an IND for Privosegtor in acute MS relapses.manilatimes.net
Why it matters
For Oculis, the presentation of strong, objective biomarker readouts from the ACUITY trial is a key step in advancing Privosegtor toward market approval. The company is focused on addressing significant unmet medical needs in neuro-ophthalmology, and positive data from Phase 2 trials is crucial for maintaining and advancing its regulatory standing with agencies like the EMA.
Optic neuritis is a rare condition that can lead to permanent visual impairment, and currently, there is no specific therapy approved to prevent vision loss after an acute episode. Privosegtor is being developed as a novel peptoid small-molecule candidate with the potential to become the first neuroprotective therapy for optic neuritis.
What we don't know yet
- What specific regulatory feedback will Oculis receive from the EMA regarding the ACUITY Phase 2 dataset?
- How will the planned IND submission for acute MS relapses proceed following this presentation?
What would change this answer
Who else could feel it
Other possible ripples from the same event.
- ADILikelyOCS's strong clinical data presentation could boost ADI's segment value.
- Securities and Exchange CommissionPossibleThe SEC must monitor OCS's disclosures following new clinical data release.
- NasdaqPossiblePositive clinical data from OCS may increase trading activity on Nasdaq
- FDAPossibleOCS's positive trial data may influence FDA review of Privosegtor
Reporting
- manilatimes.netOct 20
Keep going
Brind's analysis is written by AI from the reporting linked above and can be wrong. This explainer is a possibility worth considering, not a forecast: steps marked as Brind's reasoning are not stated in the reporting. It is not investment advice; do your own research.